Clinical Trial Results:
Efficacy of the V0034CR01B emollient on xerosis in children with atopic dermatitis. Randomised, vehicle-controlled, parallel-groups, double-blind study with an open label extension
Summary
|
|
EudraCT number |
2011-003295-37 |
Trial protocol |
FR EE LT PL |
Global end of trial date |
24 May 2012
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Feb 2016
|
First version publication date |
18 Feb 2016
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
V00034CR3121B
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01467362 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Pierre Fabre Medicament
|
||
Sponsor organisation address |
45, Place Abel Gance, Boulogne, France, 92100
|
||
Public contact |
Medical and/or Clinical Study Manager, Pierre Fabre Medicament, contact_essais_cliniques@pierre-fabre.com
|
||
Scientific contact |
Medical and/or Clinical Study Manager, Pierre Fabre Medicament, contact_essais_cliniques@pierre-fabre.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
20 Dec 2012
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
24 May 2012
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate the efficacy of V0034CR01B cream on xerosis in children with atopic dermatitis in comparison with vehicle over 28 days.
|
||
Protection of trial subjects |
Medical and clinical examination.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
30 Nov 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Poland: 59
|
||
Country: Number of subjects enrolled |
Estonia: 79
|
||
Country: Number of subjects enrolled |
France: 18
|
||
Country: Number of subjects enrolled |
Lithuania: 67
|
||
Country: Number of subjects enrolled |
Romania: 26
|
||
Worldwide total number of subjects |
249
|
||
EEA total number of subjects |
249
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
249
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
251 patients were randomised but only 249 patients were randomised and treated. 2 patients did not take any treatment (1 withdrawn patient for parents decision in each arm); safety and efficacy population was composed of 249 patients. | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
Patients who met all inclusion criteria and none of exclusion criteria were randomised into 2 groups, V0034CR01B or vehicle, and during 28 days received treatment. After this first period, according to the status of lesions and xerosis score, patients entered an open-label period for 56 days (V0034CR01B or started a treatment free follow-up). | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Double-blind period Day 1 to Day 28
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Experimental Group | |||||||||||||||||||||
Arm description |
- | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Dexeryl®
|
|||||||||||||||||||||
Investigational medicinal product code |
V0034CR01B
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||||||||
Routes of administration |
Topical use
|
|||||||||||||||||||||
Dosage and administration details |
One application twice a day (morning and evening) on the whole body including face.
When inflammatory lesions were present (disease exacerbation phases), the product was applied once a day (in the morning) on the whole body including the face, and a moderately potent corticosteroid (Locapred®) was applied once a day (in the evening) only on the lesions of the body and the face.
|
|||||||||||||||||||||
Arm title
|
Vehicle Group | |||||||||||||||||||||
Arm description |
- | |||||||||||||||||||||
Arm type |
Vehicle | |||||||||||||||||||||
Investigational medicinal product name |
Vehicle
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||||||||
Routes of administration |
Topical use
|
|||||||||||||||||||||
Dosage and administration details |
One application twice a day (morning and evening) on the whole body including face.
When inflammatory lesions were present (disease exacerbation phases), the product was applied once a day (in the morning) on the whole body including the face, and a moderately potent corticosteroid (Locapred®) was applied once a day (in the evening) only on the lesions of the body and the face.
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Period 2
|
||||||||||||||||||||||
Period 2 title |
Open-label Period Day 28 to Day 56
|
|||||||||||||||||||||
Is this the baseline period? |
No | |||||||||||||||||||||
Allocation method |
Not applicable
|
|||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Experimental Group | |||||||||||||||||||||
Arm description |
On Day 28, if patients had persisting lesions and/or xerosis score >1 at Day 28, the application of experimental treatment started (Patients from double-blind vehicle group) or continued (patients from double blind experimental group). | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Dexeryl®
|
|||||||||||||||||||||
Investigational medicinal product code |
V0034CR01B
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||||||||
Routes of administration |
Topical use
|
|||||||||||||||||||||
Dosage and administration details |
One application twice a day (morning and evening) on the whole body including face.
When inflammatory lesions were present (disease exacerbation phases), the product was applied once a day (in the morning) on the whole body including the face, and a moderately potent corticosteroid (Locapred®) was applied once a day (in the evening) only on the lesions of the body and the face.
|
|||||||||||||||||||||
Arm title
|
Treatment free follow-up Group | |||||||||||||||||||||
Arm description |
On Day 28, only patients without persisting lesions and xerosis score ≤ 1 started treatment free follow-up. | |||||||||||||||||||||
Arm type |
No intervention | |||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Period 3
|
||||||||||||||||||||||
Period 3 title |
Open-label Period Day 56 to Day 84
|
|||||||||||||||||||||
Is this the baseline period? |
No | |||||||||||||||||||||
Allocation method |
Not applicable
|
|||||||||||||||||||||
Blinding used |
Not blinded | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Experimental group | |||||||||||||||||||||
Arm description |
On day 56: if patients had persisting lesions and/or xerosis score >1 at D56, the application of experimental product started or continued. Patients treated with Experimental product between Day 28 and Day 56 could not started treatment free follow-up, even if their skin at Day 56 was free from lesions and xerosis score ≤1. | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Dexeryl®
|
|||||||||||||||||||||
Investigational medicinal product code |
V0034CR01B
|
|||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Cream
|
|||||||||||||||||||||
Routes of administration |
Topical use
|
|||||||||||||||||||||
Dosage and administration details |
One application twice a day (morning and evening) on the whole body including face.
When inflammatory lesions were present (disease exacerbation phases), the product was applied once a day (in the morning) on the whole body including the face, and a moderately potent corticosteroid (Locapred®) was applied once a day (in the evening) only on the lesions of the body and the face.
|
|||||||||||||||||||||
Arm title
|
Treatment free follow-up Group | |||||||||||||||||||||
Arm description |
Only patients without persisting lesions and xerosis score ≤1 at Day 56 continued treatment free started at Day 28. | |||||||||||||||||||||
Arm type |
No intervention | |||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
|||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Experimental Group
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Vehicle Group
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Full analysis set
|
||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All randomised patients having received at least one application of the study treatment, used to perform the analysis of safety and efficacy.
|
||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Experimental Group
|
||
Reporting group description |
- | ||
Reporting group title |
Vehicle Group
|
||
Reporting group description |
- | ||
Reporting group title |
Experimental Group
|
||
Reporting group description |
On Day 28, if patients had persisting lesions and/or xerosis score >1 at Day 28, the application of experimental treatment started (Patients from double-blind vehicle group) or continued (patients from double blind experimental group). | ||
Reporting group title |
Treatment free follow-up Group
|
||
Reporting group description |
On Day 28, only patients without persisting lesions and xerosis score ≤ 1 started treatment free follow-up. | ||
Reporting group title |
Experimental group
|
||
Reporting group description |
On day 56: if patients had persisting lesions and/or xerosis score >1 at D56, the application of experimental product started or continued. Patients treated with Experimental product between Day 28 and Day 56 could not started treatment free follow-up, even if their skin at Day 56 was free from lesions and xerosis score ≤1. | ||
Reporting group title |
Treatment free follow-up Group
|
||
Reporting group description |
Only patients without persisting lesions and xerosis score ≤1 at Day 56 continued treatment free started at Day 28. | ||
Subject analysis set title |
Full analysis set
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
All randomised patients having received at least one application of the study treatment, used to perform the analysis of safety and efficacy.
|
|
|||||||||||||
End point title |
Xerosis score : mean evolution over the different time-points of double-blind period | ||||||||||||
End point description |
The primary criterion was the change from baseline of the xerosis score over the different time-points of the double-blind period for patients included in the Full Analysis Set.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline (Day 1), Day 7, Day 14, Day 21 and Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Adjusted mean difference in change (xerosis score) | ||||||||||||
Statistical analysis description |
Analysis of the change from baseline to day 28 using a Mixed-effects Model for Repeated Measures (MMRM) (observed values from the mean changes in xerosis score at all time points up to day 28).
|
||||||||||||
Comparison groups |
Experimental Group v Vehicle Group
|
||||||||||||
Number of subjects included in analysis |
249
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.0001 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||
Point estimate |
-0.3
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-0.42 | ||||||||||||
upper limit |
-0.18 | ||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||
Dispersion value |
0.061
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
During the whole study period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
14.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Double-blind period : Experimental Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Double blind : Vehicle group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Open-Label Day 28 to Day 56 : Experimental group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Open-Label Day 28 to Day 56 : Follow-up group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Open-Label Day 56 to Day 84 : Experimental group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Open-Label Day 56 to Day 84 : Follow-up group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/24267728 |